［1］BHAMIDIPATI PK,MA FIALA,BJ GROSSMAN,et al.Results of a prospective randomized,open-label,noninferiority study of Tbo-filgrastim (granix) versus filgrastim (neupogen) in combination with plerixafor for autologous stem cell mobilization in patients with multiple myeloma and non-Hodgkin lymphoma［J］.Biol Blood Marrow Transplant,2017,23(12):2065-2069.
[2]WASZCZUK-GAJDA A,J DROZD-SOKOLOWSKA,P BOGURADZKI,et al.Stem cell mobilization in patients with dialysis-dependent multiple myeloma:Report of the Polish Myeloma Study Group［J］.J Clin Apher,2018,33(3):249-258.
[3]KOPINSKA A,M KRAWCZYK-KULIS,J DZIACZKOWSKA-SUSZEK,et al.The importance of the number of transplanted cells with dipeptidyl peptidase-4 expression on the haematopoietic recovery and lymphocyte reconstitution in patients with multiple myeloma after autologous haematopoietic stem-cell transplantation［J］.Hematol Oncol,2017,35(2):225-231.
[4]WATTS MJ,SJ INGS,C BALSA,et al.Re-evaluation of progenitor thresholds and expectations for haematopoietic recovery based on an analysis of 810 autologous transplants:Implications for quality assurance［J］.Br J Haematol,2016,175(4):673-676.
[5]HYDER MA,WS GOEBEL,KD ERVIN,et al.Low CD34(+) cell doses are associated with increased cost and worse outcome after tandem autologous stem cell transplantation in patients with relapsed or refractory germ cell tumors［J］.Biol Blood Marrow Transplant,2018,24(7):1497-1504.
[6]NATH K,R BOLES,A MCCUTCHAN,et al.The relationship between CD34+ stem cell dose and time to neutrophil recovery in autologoushaematopoietic stem cell recipients-a single centre experience［J］.Transfus Apher Sci,2018,57(4):532-536.
[7]MARTIN R,MJ RICCI,R FOLEY,et al.The relationship of CD34+ dosage and platelet recovery following high dose chemotherapy and autologous CD34+ reinfusion in multiple myeloma［J］.Transfus Apher Sci,2017,56(4):552-557.
[8]DOGU MH,H BATGI,MA ERKURT,et al.Stem cell mobilization kinetics in elderly patients with multiple myeloma［J］.Transfus Apher Sci,2018,57(2):204-207.
[9]SOLMAZ MS,D TURKYILMAZ,C ACAR,et al.Does reinfusion of stem cell products on multiple days affect engraftment［J］.Turk J Haematol,2018,35(4):271-276.
[10]ABONNENC M,B PESSE,JD TISSOT,et al.Automatic washing of thawed haematopoietic progenitor cell grafts:a preclinical evaluation［J］.Vox Sang,2017,112(4):367-378.
[11]MITRUS I,A SMAGUR,W FIDYK,et al.Reduction of DMSO concentration in cryopreservation mixture from 10% to 7.5% and 5% has no impact on engraftment after autologous peripheral blood stem cell transplantation:Results of a prospective,randomized study［J］.Bone Marrow Transplant,2018,53(3):274-280.
[12]LISENKO K,P PAVEL,M KRIEGSMANN,et al.Storage duration of autologous stem cell preparations has no impact on hematopoietic recovery after transplantation［J］.Biol Blood Marrow Transplant,2017,23(4):684-690.
[13]PAVLU J,HW AUNER,RM SZYDLO,et al.Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation［J］.Bone Marrow Transplant,2017,52(12):1599-1601.
[14]REICH-SLOTKY R,SS MAKHANI,LV VASOVIC,et al.Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products［J］.Leuk Lymphoma,2018,59(12):2829-2835.
[15]PAULSON K,SG GILPIN,TA SHPIRUK,et al.Routine filtration of hematopoietic stem cell products:the time has arrived［J］.Transfusion,2015,55(8):1980-1984.
[16]SEVINDIK OG,S KORKMAZ,F ALTUNTAS.Current status of art mobilization in myeloma［J］.Transfus Apher Sci,2017,56(6):850-853.
[17]SAHIN U,T DEMIRER.Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma［J］.J Clin Apher,2018,33(3):357-370.
[18]DOGU MH,S CAGIRGAN,S OCAKCI,et al.Autologous stem cell transplantation and stem cell mobilization kinetics in elderly patients with B cell non-Hodgkin lymphoma［J］.Transfus Apher Sci,2017,56(6):814-818.
[19]ATACA AP,OS BAKANAY,T DEMIRER.How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation［J］.Transfus Apher Sci,2017,56(2):190-198.
[20]WINKELMANN N,M DESOLE,I HILGENDORF,et al.Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients［J］.J Cancer Res Clin Oncol 2016,142(12):2603-2610.
[21]LIAO LS,TN WEI,ZH ZHENG,et al.DA-EPOCH chemotherapy combined with G-CSF effectively mobilizes autologous PBHSC in NHL patients［J］.Journal of Experimental Hematology,2017,25(6):1670-1674.
[22]JEON SY,HY YHIM,HS KIM,et al.The effect of the dexamethasone,cytarabine,and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin's lymphoma who are candidates for up-front autologous stem cell transplantation［J］.Korean J Intern Med,2018,33(6):1169-1181.
[23]BEN AN,D BELLOUMI,M MAAMMAR,et al.Peripheral blood stem cell mobilization in multiple myeloma comparison of two consecutive regimens in a limited resources country［J］.Bone Marrow Transplant,2017,52(2):222-227.
[24]WANG G,W CHEN,Y WU,et al.Recombinant human thrombopoietin improves the efficacy of intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor in mobilizing peripheral blood stem cells in patients with multiple myeloma:A cohort study［J］.Medicine (Baltimore),2017,96(50):e9302.
[25]DOUGLAS KW,M GILLEECE,P HAYDEN,et al.UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy［J］.J Clin Apher,2018,33(1):46-59.
[26]MICALLEF IN,PJ STIFF,AP NADEMANEE,et al.Plerixafor plus granulocyte colony-stimulating factor for patients with non-Hodgkin lymphoma and multiple myeloma:Long-term follow-up report［J］.Biol Blood Marrow Transplant,2018,24(6):1187-1195.
[27]VALTOLA J,R SILVENNOINEN,A ROPPONEN,et al.Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor:a prospective multicenter study［J］.Leuk Lymphoma,2019,60(2):453-461.
[28]HUBEL K,H OSTERMANN,B GLASS,et al.Plerixafor in non-Hodgkin's lymphoma patients:a German analysis of time,effort and costs［J］.Bone Marrow Transplant,2019,54(1):123-129.
[29]AYPAR E,FV IZZETTIN,SZ AKI,et al.Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients:High-dose melphalan versus high-dose melphalan and bortezomib［J］.J Oncol Pharm Pract,2018,24(4):281-289.
[30]PATEL P,AL OH,M KOSHY,et al.A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m2 and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma［J］.Leuk Lymphoma,2018,59(7):1666-1671.
[31]SWEISS K,S PATEL,K CULOS,et al.Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival［J］.Bone Marrow Transplant,2016,51(10):1337-1341.
[32]BOUTSIKAS G,E TERPOS,A PAPATHEODOROU,et al.Study of bone metabolism and angiogenesis in patients undergoing high-dose chemotherapy/autologous hematopoietic stem cell transplantation［J］.Eur J Haematol,2018,100(2):131-139.
[33]BAI L,G BEST,W XIA,et al.Expression of intracellular reactive oxygen species in hematopoietic stem cells correlates with time to neutrophil and platelet engraftment in patients undergoing autologous bone marrow transplantation［J］.Biol Blood Marrow Transplant,2018,24(10):1997-2002.
[34]RADTKE S,JE ADAIR,MA GIESE,et al.A distinct hematopoietic stem cell population for rapid multilineage engraftment in nonhuman primates［J］.Sci Transl Med,2017,9(414):1-22.